


In the Claims

1. (Previously Presented) A pharmaceutical composition having ER $\alpha$  agonist activity and having ER $\beta$  antagonist activity, comprising:

a steroid compound satisfying the following structural formula:



wherein:



one of X and Y is OH, the other being H;

R<sub>3</sub> is H or COR'<sub>3</sub>, with R'<sub>3</sub> being alkyl or aryl;

R<sub>7</sub>, R<sub>16</sub>, and R<sub>17</sub> each independently are H, alkyl, cycloalkyl, alkenyl, alkynyl or aryl; R<sub>11</sub> is a hydrocarbon group, which may be linear or branched, comprising one single linear chain having a length of from 5 to 9 carbon atoms as the longest chain on carbon atom no. 11 of the steroid skeleton, wherein said chain may be saturated or unsaturated, and

a pharmaceutical acceptable auxiliary.

2. (Currently Amended) The ~~steroid compound~~ pharmaceutical composition according to claim 1, wherein R<sub>11</sub> is selected from the following group of side-chain structures: selected from the group consisting of



wherein X is ~~CH<sub>2</sub>, CH alkyl or C(alkyl)<sub>2</sub>~~, R<sub>1</sub> is ~~H, alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or together with X forms a C<sub>3</sub>-C<sub>7</sub> ring system~~, R<sub>2</sub> is ~~H, alkyl or C<sub>3</sub>-C<sub>7</sub> cycloalkyl~~, R<sub>3</sub> and R<sub>4</sub> each independently are ~~H, alkyl or C<sub>3</sub>-C<sub>7</sub> cycloalkyl, unsubstituted or substituted with halogen or CN~~, n is an integer of ~~from 0-9~~, m is an integer of ~~from 1-5~~.

3. (Previously Presented) The pharmaceutical composition according to claim 1, wherein the longest chain in  $R_{11}$  comprises 5-7 carbon atoms.

4. (Previously Presented) The pharmaceutical composition according to claim 3, wherein the longest chain in  $R_{11}$  comprises 5 carbon atoms.

5. (Canceled).


6. (Canceled).

7. (Previously Presented) A method for treating estrogen deficiency disorders, comprising:

administering to a patient afflicted with an estrogen deficiency disorder an effective amount of the pharmaceutical composition of claim 1.

8. (Previously Presented) A method of inducing  $ER\alpha$  agonist activity and  $ER\beta$  antagonist activity in a patient in need thereof, comprising:

administering an effective amount of a steroid compound satisfying the following structural formula:



formula I

wherein:

one of X and Y is OH, the other being H;

$R_3$  is H or  $COR'_3$ , with  $R'_3$  being alkyl or aryl;

$R_7$ ,  $R_{16}$ , and  $R_{17}$  each independently are H, alkyl, cycloalkyl, alkenyl, alkynyl or aryl;

$R_{11}$  is a hydrocarbon group, which may be linear or branched, comprising one single linear chain having a length of from 5 to 9 carbon atoms as the longest chain on carbon atom no. 11 of the steroid skeleton, wherein said chain may be saturated or unsaturated.

9. (Canceled).

10. (Canceled).

11. (Canceled).

12. (Canceled).